BMS
Deep Dive/ Sales and Marketing/ Views & Analysis/ Views and analysis
Deep Dive: Communications and Commercialisation
mike.hammerton@pharmaphorum.com
BMS, commercialisation, communications, Deep Dive, Deep Dive: Communications and Commercialisation, digital HCP engagement, HCP communication, HCP engagement, patient centricity
0 Comment
Market Access/ Oncology/ R&D/ Views & Analysis/ Views and analysis
New Cell & Gene Therapy Collective seeks to boost UK adoption
George Underwood
Astellas, bluebird bio, BMS, Cell & Gene Collective, cell and gene therapy, cell therapy, gene therapy, Gilead, Kite, Novartis, UK
0 Comment
Digital/ Patients/ Views & Analysis/ Views & Analysis/ Views and analysis
BMS launches digital Advocacy Exchange for patient groups affected by COVID-19
George Underwood
BMS, Bristol-Myers Squibb, coronavirus, COVID-19, Digital Health & COVID-19, Gryt Health, patient groups, patient organisations, Pharma’s Digital Response to COVID-19
0 Comment
Oncology/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis
ASCO 2020 round-up: Virtual conference still delivers the drama
Richard Staines
Amgen, asco, AstraZeneca, BMS, Bristol-Myers Squibb, cancer, CAR T, coronavirus, COVID-19, Keytruda, Kyprolis, Merck & Co, Tagrisso
0 Comment
R&D/ Views & Analysis/ Views and analysis
The future of real world evidence
mike.hammerton@pharmaphorum.com
BMS, Bristol-Myers Squib, Pfizer, real world data, Real World Evidence, RWD, RWE
0 Comment
Views & Analysis/ Views and analysis
2019: the year of the pharma mega-merger
Richard Staines
AbbVie, Allergan, Biogen, BMS, Celgene, M&A, Merck & Co, Novartis, Pfizer, Roche, Shire, Takeda
0 Comment